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Abstract
Background: Molecular biomarkers assisting risk-group assignment and subsequent treatment stratification are
urgently needed for patients with squamous cell cancer of the head and neck region (HNSCC). Aberrant
methylation is a frequent event in cancer and, therefore, a promising source for potential biomarkers. Here,
the methylation status of the paired-like homeodomain transcription factor 3 (PITX3) was evaluated in HNSCC.
Methods: Using a quantitative real-time PCR, PITX3 methylation was assessed in a cohort of 326 HNSCC patients treated
for localized or locally advanced disease (training cohort). The results were validated with Infinium HumanMethylation450
BeadChip data from a 528 HNSCC patient cohort (validation cohort) generated by The Cancer Genome Atlas (TCGA)
Research Network.
Results: PITX3 methylation was significantly higher methylated in tumor compared to normal adjacent tissue
(NAT; training cohort: median methylation NAT 32.3%, tumor 71.8%, p < 0.001; validation cohort: median
methylation NAT 16.9%, tumor 35.9%, p < 0.001). PITX3 methylation was also significantly correlated with
lymph node status both in the training (p = 0.006) and validation (p < 0.001) cohort. PITX3 methylation was
significantly higher in HPV-associated (p16-positive) tumors compared to p16-negative tumors (training cohort:
73.7 vs. 66.2%, p = 0.013; validation cohort: 40.0 vs. 33.1%, p = 0.015). Hypermethylation was significantly
associated with the risk of death (training cohort: hazard ratio (HR) = 1.80, [95% confidence interval (CI)
1.20–2.69], p = 0.005; validation cohort: HR = 1.43, [95% CI 1.05–1.95], p = 0.022). In multivariate Cox analyses,
PITX3 added independent prognostic information. Messenger RNA (mRNA) expression analysis revealed an
inverse correlation with PITX3 methylation in the TCGA cohort.
Conclusions: PITX3 DNA methylation is an independent prognostic biomarker for overall survival in patients
with HNSCC and might aid in the process of risk stratification for individualized treatment.
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Background
With an estimated incidence of more than 60,000 cases in
the USA alone, cancer of the head and neck region is a
common malignant disease. In male patients, cancer of the
oral cavity and pharynx is the eighth most common cancer
type. For 2016, 13,190 patients are estimated to succumb
to the disease [1]. The most prevalent histological subtype
in the head and neck region is squamous cell carcinoma
(HNSCC), and common risk factors are the concurrent
abuse of tobacco and alcohol as well as infections with a
high-risk human papillomavirus (HPV) like HPV16 and
HPV18. Depending on the causative agent, distinct differ-
ences have been recorded with regard to molecular alter-
ations, tumor site, and prognosis of the tumors. While
TP53 mutations are the most common alterations in
smoking-related cancers, HPV-associated tumors predom-
inantly harbor PIK3CA mutations [2]. Moreover, patients
with HPV-associated tumors tend to be younger, and
tumors are more likely to develop in the oropharynx. Not-
ably, these patients also have a better overall survival [3].
Most patients present in an advanced stage of disease.
Surgery or radiation therapy with concurrent chemother-
apy are first-line treatment options for HNSCC patients,
but local and distant failure is common [4]. Newer drugs
like the anti-EGFR antibody cetuximab have been suc-
cessfully implemented into the therapeutic portfolio of
HNSCC [5]. Combined with standard platinum-based
chemotherapy, they provide a significant overall survival
benefit for patients with recurrent or metastatic disease.
For the same patient group, immunotherapy agents like
the immune checkpoint inhibitor pembrolizumab have
recently shown high efficacy [6]. Based on these results,
pembrolizumab has recently been approved by the US
Food and Drug Administration (FDA) for patients with
recurrent or metastatic HNSCC. Considering the dismal
prognosis in the event of metastatic or recurrent disease,
such advances in drug therapy are urgently needed [7].
As yet, no prognostic molecular biomarkers have been
established to assist clinicians in stratifying treatment
or surveillance options after initial curative treatment.
Currently, clinicopathological parameters like lymph node
metastasis or tumor stage serve to identify high-risk
patients. Additional biomarkers would be of utmost value
to influence treatment strategy and surveillance intensity.
With regard to emerging immunotherapy options that
have an improved safety and side-effect profile, mo-
lecular biomarkers could distinguish patient subgroups
that would benefit from adjuvant or neoadjuvant therapy.
These biomarkers could further be evaluated in conjunc-
tion with other newly identified adverse risk factors like
delayed time to treatment [8].
Tissue-based biomarkers have already been established
for other tumor entities. In breast carcinoma, the com-
mercially available multi-gene panel assay Oncotype DX©
estimates risk of recurrence after first-line treatment for
early stage breast cancer by analyzing the expression of 21
genes [9]. Patients who have been identified as high risk
based according to the subsequently calculated recurrence
score may profit from intensified surveillance or adjuvant
chemotherapy. Another promising biomarker approach is
the investigation of the methylation status in a tumor sam-
ple. Epigenetic regulation is conferred through methylation,
and malignant tumors are frequently hyper- or hypomethy-
lated. Depending on the locus, methylation can result in
gene transcription or repression [10]. Methylation analysis
has already changed clinical practice for glioblastoma treat-
ment, where promoter methylation of MGMT is predictive
of response to the drug temozolomide [11]. So far, this is
the only clinically implemented DNA methylation-based
predictive biomarker test. DNA methylation can be quanti-
fied reliably and reproducibly via microarray, sequencing, or
real-time PCR after bisulfite conversion of DNA [12–14].
Moreover, due to the stability of DNA methylation, the
methylation status can be easily obtained even from de-
graded material like formalin-fixed paraffin-embedded
(FFPE) tissue [15], which represents the most common
clinically relevant sample material. Thus, studying epigen-
etic alterations is a promising approach for the development
of biomarkers. Several epigenetic biomarkers have been
tested in HNSCC, sometimes with conflicting results [16].
Hypermethylation of TIMP3 and CCNA1, for instance, have
been associated with an increased risk of developing second
primary tumors [17]. Hypermethylation of a gene panel
in salivary samples prior to treatment was shown to be
prognostic of local recurrence and overall survival [18].
Consequently, epigenetic markers are emerging as prog-
nostic tools in patients with HNSCC.
The paired-like homeodomain transcription factor 3
(PITX3), located on chromosome 10q24 [19], plays an
important role in the midbrain dopamine system deve-
lopment, and single-nucleotide polymorphisms within the
PITX3 gene have been associated with Parkinson’s disease
[20]. While the role of PITX3 in the brain development
has been well characterized, its contribution to tumori-
genesis remains more elusive. It has been found to be
hypermethylated in breast cancer tumors [21]. Recently,
Holmes et al. reported that PITX3 promoter methylation
is strongly associated with biochemical recurrence-free
survival in prostate cancer patients [22].
PITX3 shares a sequence similarity and at least partly
redundant function with the paired-like homeodomain
2 (PITX2) [21, 23]. PITX2 promoter methylation is a
well studied prognostic biomarker in various cancers,
i.e. prostate, breast, and biliary tract cancers [24–31].
Recent studies investigating the methylation status of
PITX2 in HNSCC and lung cancer cohorts found that
hypermethylation was associated with improved survival
[32, 33]. An in vitro diagnostic (IVD) test for anthracycline
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sensitivity in breast cancer patients based on PITX2
methylation is currently being developed for commercial
distribution by the company Therawis GmbH (Munich,
Germany). Similar to PITX2, the closely related tran-
scription factor PITX1 plays a role in the embryonal
development [34]. PITX1 has been found to be predictive
of chemosensitivity in a small HNSCC cohort [35].
Given the need for new prognostic biomarkers for
patients with curatively treated HNSCC and the promis-
ing results regarding PITX2 methylation as a biomarker,




The training cohort comprised 326 retrospectively enrolled
HNSCC patients treated at the University Hospital Bonn.
Clinical data were obtained for the majority of patients.
The study was approved by the Institutional Review Board
of the University Hospital Bonn, which waived the need for
written informed consent. The validation cohort consisted
of 528 HNSCC patients analyzed by The Cancer Genome
Atlas (TCGA) Research Network (http://cancergenome.
nih.gov/). All experiments were conducted in accordance
with the Helsinki Declaration of 1975.
Sample preparation, DNA extraction, and bisulfite
conversion
Freshly cut sections from FFPE blocks were stained
with hematoxylin and eosin. The tumor area was anno-
tated and macrodissected from unstained slides for
subsequent methylation analysis. The process of DNA
extraction and bisulfite conversion was performed using
the innuCONVERT Bisulfite All-In-One Kit (Analytik
Jena, Germany) as previously reported [36]. In order to
assess HPV status, the surrogate marker p16 was evalu-
ated by immunohistochemistry.
DNA and messenger RNA (mRNA) from samples from
the validation cohort were prepared as described by the
TCGA Research Network (www.cancergenome.nih.gov).
PITX3 quantitative methylation analysis
For the training cohort, quantitative PITX3 methylation
analysis was performed by means of quantitative real-
time PCR (qPCR) with primers and probes as previously
described [22]. The analytical performance of the qPCR
assay has been characterized earlier [22].
For the validation cohort, DNA methylation data were
generated by the TCGA Research Network using the
Infinium HumanMethylation450 BeadChip (Illumina,
Inc., San Diego, CA, USA). HumanMethylation450 data
of level 2 were downloaded directly from the TCGA
webpage. The data files included background-corrected
methylated (bead_M) and unmethylated (bead_U) bead
pair summary intensities as extracted by the R package
‘methylumi’. The bead pair (cg20023259) in proximity to
the locus of the qPCR assay was selected. Methylation
values for the bead pair were calculated by the formula
100% × bead_M/(bead_M + bead_U). The position of the
qPCR assay and the bead pair cg20023259 within the
PITX3 gene is shown in Fig. 1.
PITX3 mRNA expression analysis
The PITX3 mRNA data obtained from the TCGA Re-
search Network were generated by means of the Illumina
HiSeq 2000 RNA Sequencing version 2 analysis (Illumina,
Inc., San Diego, CA, USA) as described by the TCGA
Research Network (www.cancergenome.nih.gov). PITX3
mRNA expression (normalized counts) data of level 3
were downloaded from the TCGA webpage.
Statistical analysis
Statistical analyses were performed using SPSS, version 24
(SPSS Inc., Chicago, IL, USA). Bivariate correlations were
tested using the Spearman rank correlation coefficient (ρ).
Overall survival analyses were conducted by Kaplan-Meier
and Cox proportional hazards regression analyses. The
Mann-Whitney U test and one-way analysis of variance
(one-way ANOVA) were employed for the comparison of
groups. p values <0.05 were considered significant.
Results
PITX3 DNA methylation and mRNA expression in HNSCC
tissue
The results from the validation cohort are entirely
based upon data generated by the TCGA Research
Network. The PITX3 locus was highly methylated in
tumor tissues from the training and the validation co-
hort. Histograms of PITX3 methylation frequencies in
both cohorts are shown in Fig. 2a, c. In the training
cohort, methylation data were available for 466 pa-
tient samples including 140 normal and 326 tumor
tissue samples. The comparison of PITX3 methylation
in tumor and normal adjacent tissue (NAT) revealed
a significant difference between tumor tissue (mean
69.0%, median 71.8%) and NAT (mean 32.1%, median
32.3%; p < 0.001; Fig. 2b). Methylation ranged from 0.79 to
100% in tumor tissue and from 0 to 82.1% in normal
tissue. This finding was confirmed in the validation
cohort, in which methylation data were available for
578 patient samples including 50 normal and 528 tumor
tissue samples. Methylation was significantly different
between tissue types (p < 0.001; Fig. 2d) and ranged from
6.9 to 76.3% in tumor tissue (mean 36.5%, median 35.9%)
and from 11.7 to 26.1% in normal tissue (mean 17.1%,
median 16.9%). The methylation differences observed
between the two analyzed cohorts might be caused by
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Fig. 1 Genomic organization and assay position. Genomic organization of the PITX3 gene and locations of the PITX3 qPCR assay [22]
and the Infinium HumanMethylation450 BeadChip bead cg20023259. The information was obtained from Ensembl Homo sapiens
version GRCh38.p7
Fig. 2 PITX3 DNA methylation in HNSCC specimens. Frequency of PITX3 DNA methylation in the training cohort (a) comprising 326 HNSCC
patients and validation cohort (b) including 528 HNSCC patients. Shown are the methylation levels in tumor tissue only. PITX3 DNA methylation
in tumor tissue compared to normal adjacent tissue from the training (c) and the validation (d) cohort, respectively. Tumor tissue was methylated
significantly higher compared to corresponding normal adjacent tissue. p values refer to Wilcoxon-Mann-Whitney test
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Table 1 Association of clinicopathological parameters with PITX3 methylation in HNSCC patients of the training cohort (n = 326) and
the validation cohort (n = 528)
Training cohort Validation cohort (TCGA)
Variable No. (%) of patients Mean PITX3 methylation (%) p value No. (%) of patients Mean PITX3 methylation (%) p value
All patients 326 (100) 69.0 528 (100) 36.5
Sex 0.58 0.42
Female 74 (22.7) 68.0 142 (26.9) 35.6
Male 252 (77.3) 69.3 386 (73.1) 36.8
Age (years) 0.16 0.32
Mean 62.2 60.9
Median 62 0.55 61 0.48
n <Median 132 (40.5) 70.3 282 (53.4) 36.1
n >Median 119 (36.5) 71.7 245 (46.4) 36.9
Unknown 75 (23.0) 1 (0.2)
Smoking status 0.91 0.92
Non-smoker 25 (7.7) 69.8 122 (23.1) 36.7
Smoker 178 (54.6) 70.2 393 (74.4) 36.6
Unknown 123 (37.7) 13 (2.5)
Pack years 0.17 0.60
<40 92 (28.2) 72.0 168 (31.8) 36.5
>40 46 (14.1) 76.0 130 (24.6) 37.3
Unknown 188 (57.7) 230 (43.6)
Alcohol consumption 0.10 0.37
Yes 81 (24.8) 74.8 352 (66.7) 37.0
No 47 (14.4) 69.8 165 (31.3) 35.9
Unknown 198 (60.7) 11 (2.1)
Tumor site 0.023a 0.017a
Oral cavity 50 (15.3) 69.0 320 (60.6) 36.6
Oropharynx 139 (42.6) 72.0 81 (15.3) 40.2
Hypopharynx 22 (6.7) 72.8 10 (1.9) 33.6
Larynx 95 (29.1) 67.0 117 (22.2) 33.9
Unknown 20 (6.1)
pT 0.80 0.22
T1/T2 160 (49.1) 69.8 190 (36.0) 34.9
T3/T4 119 (36.5) 69.2 276 (52.3) 36.5
Unknown 47 (14.4) 62 (11.7)
pN 0.006a <0.001a
N0 128 (39.3) 66.3 180 (34.1) 32.8
N1/2/3 173 (53.1) 72.0 240 (45.5) 37.7
Unknown 25 (7.7) 108 (20.5)
p16 0.013a 0.015a
Negative 200 (61.3) 66.2 74 (14) 33.1
Positive 51 (15.6) 73.7 41 (7.8) 40.0
Unknown 75 (23.0) 413 (78.2)
Grade 0.40 0.33
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the application of two different technologies: qPCR and
Infinium HumanMethylation450K BeadChip.
Furthermore, DNA methylation was shown to be
inversely correlated with PITX3 mRNA (p = 0.036) in
the validation cohort. Interestingly, mRNA levels were
also significantly different in tumor (mean 6.55 normalized
counts) compared to normal (mean 15.37 normalized
counts) tissue (p < 0.001).
Association of PITX3 DNA methylation with
clinico-pathological parameters
Both in the training and validation cohort, PITX3 DNA
methylation was significantly associated with lymph node
status (p = 0.006 and p < 0.001, respectively). Moreover, a
significant methylation difference was found in regard to
HPV status in the training cohort. Using p16 as surrogate
marker, p16-negative tumors were significantly lower
methylated than p16-positive tumors (66.2 vs. 73.7%,
p = 0.018). This was confirmed in the validation cohort:
HPV-associated (p16-positive) tumors were significantly
highly methylated than p16-negative tumors (40.0 vs.
33.1%, p = 0.015). In addition, a significant difference in
methylation was found when analyzing tumor site in both
cohorts (training cohort: p = 0.023, validation cohort:
p = 0.017). A detailed analysis of both cohorts can be
found in Table 1.
Association of PITX3 DNA methylation with survival
Higher PITX3 DNA methylation analyzed as continuous
variable showed a strong trend towards poorer overall
survival in the training cohort (Hazard ratio (HR) = 1.01,
[95% confidence interval (95%CI) 1.00–1.02], p = 0.061).
PITX3 DNA methylation levels were subsequently dichot-
omized using an optimized cut-off (72.5%). PITX3 DNA
hypermethylation was significantly associated with an
increased risk of disease-related death in univariate Cox
proportional hazards (HR = 1.80, [95%CI 1.20–2.69],
p = 0.005; Table 2) and Kaplan-Meier (p = 0.004; Fig. 3a)
analyses. In addition, p16 expression and N category
were significantly associated with survival (Table 2).
Furthermore, vascular invasion (V) was significantly asso-
ciated with poor overall survival (HR = 3.51, [95%CI
1.90–6.47], p < 0.001).
Interestingly, when performing a subgroup analysis
among patients with p16-negative tumors, patients with
PITX3 hypermethylated tumors revealed an HR of 2.44
([95%CI 1.44–4.14], p = 0.001) compared to patients with
hypomethylated cancers. This finding was confirmed in
Kaplan-Meier analysis (p = 0.001; Fig. 3b). No significant
survival differences were seen in PITX3-stratified patients
with HPV-positive tumors. In a multivariate analysis,
PITX3 methylation status added independent prognostic
information (HR = 2.28, [95%CI 1.29–4.00], p = 0.004;
Table 1 Association of clinicopathological parameters with PITX3 methylation in HNSCC patients of the training cohort (n = 326) and
the validation cohort (n = 528) (Continued)
1 7 (1.8) 62.3 63 (11.9) 34.7
2 199 (49.9) 70.1 311 (58.9) 36.3
3 107 (26.8) 68.8 125 (23.7) 37.5
4 0 (0) 7 (1.3) 43.5
Unknown 86 (21.6) 22 (4.2)
Surgical margin 0.18 0.40
Negative 225 (69.0) 69.7 407 (77.1) 36.0
Positive 41 (12.6) 65.6 60 (11.4) 37.6
Unknown 60 (18.4) 61 (11.6)
Second tumor 0.070 NA
Yes 38 (11.7) 72.7
No 140 (42.9) 77.9
Unknown 148 (45.4) 528 (100)
Vascular invasion 0.083 0.072
Yes 22 (6.7) 63.0 124 (23.5) 38.4
No 170 (52.1) 70.1 232 (43.9) 35.6
Unknown 134 (41.1) 172 (32.6)
Mann-Whitney U test for sex, age (dichotomized), smoking status, pT, p16, surgical margin, second tumor, lymphovascular invasion, and pack years; One-way
ANOVA for alcohol consumption, lymph node, grade, and tumor site; Spearman’s rank correlation for age. Results from the validation cohort are entirely based
upon the data generated by the TCGA Research Network: http://cancergenome.nih.gov/
NA data not available
asignificance
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Table 2) about the risk of dying. Vascular invasion status
was excluded from multivariate analysis due to largely
missing data from both cohorts.
The prognostic biomarker performance was validated in
the TCGA cohort. Data were dichotomized by means of
an optimized cut-off (35.1%). Univariate analysis showed a
significant risk of death for patients with hypermethylated
tumors (HR = 1.43, [95%CI 1.05–1.95], p = 0.022). In a
multivariate Cox proportional hazard analysis, PITX3
methylation added significant prognostic information to T
and N category for PITX3 methylation as dichotomized
variable (HR = 1.49, [95%CI 1.02–2.16], p = 0.038; Table 3).
However, mRNA expression analyzed as a continuous
variable did not reveal any prognostic significance
(HR = 1.00, [95%CI 0.98–1.02]; p = 0.74). The introduc-
tion of an optimized cut-off (normalized counts: 13.52)
classified 58 patients as PITX3 mRNA expression-
positive and 462 patients as negative. Only a trend
towards a better prognosis of expression-positive patients
was found (HR = 0.59, [95%CI 0.34–1.03], p = 0.062).
Discussion and conclusions
Squamous cell cancer of the head and neck region poses
a substantial global health burden and affects patients
with a history of nicotine and alcohol abuse as well as
patients harboring oral infections with high-risk HPV.
The disease poses a large health burden worldwide.
Surgery and radiotherapy are the mainstay of therapy
with curative intent. Recent advantages in reconstructive
techniques may help to reduce morbidity after extensive
surgery of radiation-induced damage [37–39]. For patients
undergoing curative therapy, biomarkers are urgently
needed to identify individuals who are likely to experience
tumor recurrence or metastasis and subsequent disease-
related death. These patients could benefit from intensi-
fied surveillance or adjuvant therapy. Moreover, new
immunotherapeutic drugs are emerging from which
high-risk patients might benefit.
Epigenetic alterations in form of hypo- or hypermethy-
lated DNA are frequent events in cancer. Investigating the
DNA methylation status in patients with malignant
Table 2 Univariate and multivariate Cox proportional hazard analysis of overall survival of HNSCC patients in the training
cohort (n = 307)
Univariate Multivariate
Variable HR (95%CI) p value HR (95%CI) p value
PITX3 methylation (dichotomized, optimized cut-off 72.5%) 1.80 (1.20–2.69) 0.005a 2.28 (1.29–4.00) 0.004a
p16 expression (neg. reference) 0.40 (0.20–0.81) 0.010a 0.27 (0.11–0.67) 0.005a
N category 1.28 (1.07–1.53) 0.008a 1.27 (0.97–1.67) 0.82
T category 1.14 (0.96–1.36) 0.14 1.33 (1.03–1.72) 0.029a
Nineteen patients from the 326 patients of the cohort were omitted from survival analysis due to missing follow-up data
NA not analyzed
asignificant feature
Fig. 3 Overall survival in patients stratified according to PITX3 DNA methylation. Kaplan-Meier analysis of overall survival in HNSCC patients stratified
according to PITX3 DNA methylation levels in tumor tissue. a Training cohort (all patients). b Training cohort (p16-negative patients). c Validation cohort
(all patients). High PITX3 DNA methylation was associated with an adverse prognosis in both cohorts, in particular in p16-negative patients from the
training cohort. A subgroup analysis of p16-negative patients from the validation cohort was not performed due to largely missing data
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diseases is a promising approach to establish new bio-
markers. In the present study, PITX3 DNA methylation
was analyzed in a well-annotated HNSCC cohort from the
University Hospital Bonn. In multivariate analysis, PITX3
DNA hypermethylation was significantly associated with
the risk of death. These results were validated in a HNSCC
cohort from the TCGA Research Network. Furthermore,
hypermethylation correlated inversely with PITX3 mRNA
expression in the TCGA cohort. Although these findings
lead to the conclusion that hypermethylation is associated
with silencing of the PITX3 gene, the transcriptional
relevance remains unclear. Hypomethylation may result
in transcription of the gene; however, the role of PITX3
in tumorigenesis has not been described. One possible
mechanism could be the co-transcription of other genes
on chromosome 10q such as suppressor of fused homo-
log (SUFU), which acts as a negative regulator of the
hedgehog signaling pathway. Combined loss of SUFU and
p53 results in the development of medulloblastomas and
rhabdomyosarcoma in mice [40]. Hedgehog signaling
may also play a role in HNSCC tumorigenesis. Hence,
the transcription of a negative regulator could result in a
reduced tumor growth [41]. It has previously been shown
that HPV infection may result in alteration of the DNA
methylome. Therefore, HPV-mediated epigenetic alter-
ations may account for the hypermethylation in HPV-
positive tumors described in the present study [42, 43].
However, SUFU and PITX3 are not located on the
immediately neighboring regions of 10q24. It is therefore
unclear whether methylation of PITX3 could have any
influence on SUFU transcription.
In a rat model for prostate cancer development follow-
ing exposure to endocrine-disrupting chemicals, PITX3
was found to be one of several hypomethylated and there-
fore expressed genes [44]. While this model cannot serve
as a model for HNSCC tumorigenesis, it is an interesting
finding and possibly allows for the implication of PITX3
alteration being an early event in cancer development.
This would be in line with the results of Holmes et al.,
who were able to show that PITX3 methylation is a strong
prognostic marker for biochemical recurrence in localized
prostate cancer [22].
HNSCC display a high genomic instability with a mean
of 141 copy number alterations per tumor, including
amplification of 10q24 [45, 46]. Since amplification
has been associated with hypermethylation, this might
provide an explanation for the observed methylation
differences [47]. Even though the biological function
remains unclear for now, PITX3 DNA methylation
status emerges as a promising biomarker particularly
for patients with HPV-negative tumors.
In brief, this is the first study to show that the methyla-
tion status of PITX3 is an independent prognostic factor
for overall survival in patients with HNSCC. These findings
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